BidaskClub Lowers NeoGenomics (NASDAQ:NEO) to Sell

BidaskClub lowered shares of NeoGenomics (NASDAQ:NEO) from a hold rating to a sell rating in a research note issued to investors on Saturday, BidAskClub reports.

A number of other analysts have also recently issued reports on NEO. Zacks Investment Research upgraded shares of NeoGenomics from a sell rating to a hold rating in a research note on Tuesday, November 5th. William Blair reiterated an outperform rating on shares of NeoGenomics in a research note on Tuesday, October 29th. ValuEngine upgraded shares of NeoGenomics from a hold rating to a buy rating in a research note on Friday, November 1st. Benchmark set a $27.00 price objective on shares of NeoGenomics and gave the stock a buy rating in a research note on Wednesday, July 31st. Finally, Needham & Company LLC lifted their price objective on shares of NeoGenomics from $27.00 to $29.00 and gave the stock a buy rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $24.86.

NeoGenomics stock traded up $0.68 during mid-day trading on Friday, reaching $22.69. The company’s stock had a trading volume of 494,000 shares, compared to its average volume of 995,542. The business’s 50 day simple moving average is $20.68 and its 200 day simple moving average is $22.52. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.05 and a current ratio of 4.24. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of 174.54 and a beta of 0.94. NeoGenomics has a 12 month low of $11.05 and a 12 month high of $26.89.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $104.70 million during the quarter, compared to analysts’ expectations of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. NeoGenomics’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.05 EPS. As a group, sell-side analysts expect that NeoGenomics will post 0.19 EPS for the current year.

In other news, Director Steven C. Jones sold 1,691 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $25.00, for a total value of $42,275.00. Following the completion of the transaction, the director now directly owns 245,234 shares in the company, valued at approximately $6,130,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steven C. Jones sold 40,737 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $25.02, for a total transaction of $1,019,239.74. Following the completion of the transaction, the director now owns 245,234 shares of the company’s stock, valued at $6,135,754.68. The disclosure for this sale can be found here. Insiders sold a total of 363,399 shares of company stock valued at $8,822,819 in the last quarter. Corporate insiders own 8.80% of the company’s stock.

Large investors have recently modified their holdings of the company. NEXT Financial Group Inc raised its position in shares of NeoGenomics by 200.0% in the 2nd quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock valued at $59,000 after buying an additional 1,800 shares in the last quarter. Captrust Financial Advisors acquired a new position in shares of NeoGenomics in the 2nd quarter valued at approximately $66,000. Nisa Investment Advisors LLC raised its position in shares of NeoGenomics by 867.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock valued at $74,000 after buying an additional 3,470 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its position in shares of NeoGenomics by 75.0% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock valued at $87,000 after buying an additional 1,950 shares in the last quarter. Finally, Winslow Evans & Crocker Inc. acquired a new position in shares of NeoGenomics in the 2nd quarter valued at approximately $92,000. Institutional investors own 85.02% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Article: Accumulation/Distribution

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.